Literature DB >> 17470751

Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS.

Jorge Sepulcre1, Manuel Murie-Fernandez, Angel Salinas-Alaman, Alfredo García-Layana, Bartolome Bejarano, Pablo Villoslada.   

Abstract

OBJECTIVES: To assess the association between the thickness of the retinal nerve fiber layer (RNFL), assessed by optical coherence tomography (OCT), retinal periphlebitis (RP), and multiple sclerosis (MS) disease activity.
METHODS: We studied a prospective cohort of 61 patients and 29 matched controls for 2 years, performing a neurologic assessment every 3 months and an ophthalmologic evaluation, including OCT scans, every 6 months. Baseline MRI studies were also carried out from which brain volume and lesion load were assessed.
RESULTS: We found that the RNFL thickness in patients with MS was thinner than in controls, particularly in the temporal quadrant (p = 0.004). Although RNFL atrophy was greater in patients who also had optic neuritis (p = 0.002), it also augmented in MS patients who did not have optic neuritis compared with controls (p = 0.014). RNFL atrophy was correlated with greater disability (r = -0.348, p = 0.001) and longer disease duration (r = -0.301, p = 0.003). Furthermore, baseline temporal quadrant RNFL atrophy was associated with the presence of new relapses and changes in the Expanded Disability Status Scale by the end of the study (p < 0.05 in all cases). Indeed, RNFL thickness was correlated with white matter volume (r = 0.291, p = 0.005) and gray matter volume (r = 0.239, p = 0.021). The presence of RP was a risk factor for having new relapses in the next 2 years (odds ratio = 1.52, p = 0.02), and patients with RP had larger gadolinium-enhancing lesions volume (p = 0.003).
CONCLUSION: Retinal nerve fiber layer atrophy and the presence of retinal periphlebitis are associated with disease activity, suggesting that retinal evaluation can be used as biomarkers of multiple sclerosis activity.

Entities:  

Mesh:

Year:  2007        PMID: 17470751     DOI: 10.1212/01.wnl.0000260612.51849.ed

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  89 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

3.  Comparison of retinal nerve fiber layer measured by time domain and spectral domain optical coherence tomography in optic neuritis.

Authors:  G Rebolleda; A García-García; H R Won Kim; F J Muñoz-Negrete
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

4.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

Review 5.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis.

Authors:  Madhan Kolappan; Andrew P D Henderson; Thomas M Jenkins; Claudia A M Wheeler-Kingshott; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

Review 7.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

Review 8.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

Review 9.  [Diagnosis and monitoring of multiple sclerosis: the value of optical coherence tomography].

Authors:  M Bock; F Paul; J Dörr
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 10.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.